Neotame: Physiology and What Research Reports

What Neotame Is

Neotame is a high-intensity sweetener authorised as a food additive and identified in the European Union by the number E 961. Structurally it belongs to the same family as aspartame: its core is a dipeptide methyl ester formed from aspartic acid and phenylalanine, joined by a peptide bond, with a methyl ester on the phenylalanine carboxyl group. The feature that distinguishes neotame from aspartame is a 3,3-dimethylbutyl (neohexyl) group attached to the amino nitrogen of the aspartate residue.

Because of that backbone, neotame is often the first "peptide-adjacent" molecule readers encounter outside of therapeutic peptides. It is not a hormone, not a signalling peptide and not a research peptide in the pharmacological sense. It is a small synthetic molecule whose peptide bond and ester group make it a useful teaching example of how amino-acid-based structures behave during processing, storage and digestion.

Where It Comes From and What Happens to It in the Body

Neotame is produced synthetically rather than secreted by any tissue, so unlike endogenous peptides it has no physiological site of production, no circadian pattern and no receptor system that the body uses for its own signalling. Its interaction with human physiology begins at the sweet-taste receptor complex on the tongue, where it produces a sweet sensation at very low concentrations, and continues through the gastrointestinal tract, where an amino-acid-based ester is exposed to gastric acid, pancreatic enzymes and intestinal esterases.

The fate of the molecule after ingestion — absorption, hydrolysis of the ester group, metabolism of the resulting fragments and excretion — is exactly the kind of dataset that regulatory reviews assemble. The European Food Safety Authority carried out a re-evaluation of neotame (E 961) as a food additive, published in 2025, which considered the available toxicological and exposure data for the additive (PMID 40626198). Readers who want the primary account of absorption, distribution, metabolism and excretion assumptions should go to that document rather than to secondary summaries.

How Neotame Is Measured and Studied

Three broad research approaches appear in the literature, and they answer different questions.

• Analytical chemistry. Quantifying how much intact neotame remains in a food matrix after heating or storage, typically by chromatographic separation and detection of the parent compound and its degradation products.
• Human feeding trials. Substituting neotame for sugar in a food vehicle and measuring subjective appetite ratings alongside blood markers such as glucose and gut or pancreatic hormones after eating.
• Regulatory risk assessment. Pooling animal toxicology, genotoxicity, metabolism and dietary exposure estimates into a single opinion on the additive's acceptability, as in the 2025 re-evaluation of E 961 (PMID 40626198).

What the Literature Reports

Stability in heat-treated foods

Stability matters because a peptide-based sweetener can lose sweetness if its peptide bond or ester hydrolyses during processing. A 2016 food chemistry study examined the stability of aspartame and neotame in flavoured milk that had been pasteurised and, separately, in-bottle sterilised, and the researchers reported that neotame was the more stable of the two sweeteners under those heat treatments and subsequent storage (PMID 26593524). For peptide readers, the study is a clean illustration of how an N-alkyl substitution on an amino-acid backbone can change how a molecule survives thermal stress (PMID 26593524).

Appetite and endocrine response in a human crossover trial

A randomised crossover trial from the SWEET consortium, published in 2024, compared biscuits sweetened with neotame, with stevia rebaudioside M, or with sucrose in adults with overweight or obesity, and assessed both acute and two-week effects on postprandial appetite and endocrine response (PMID 38553262). The study measured subjective appetite alongside circulating endocrine markers after the test meals, and the researchers reported that substituting the sweeteners for sucrose did not worsen postprandial appetite or the endocrine response over the periods studied (PMID 38553262). The trial used food products rather than isolated sweetener doses, and its findings apply to that context and to the population enrolled (PMID 38553262).

Adverse Events and Safety Assessments: What Studies Report

The most complete public account of potential harms is the regulatory re-evaluation rather than any single experiment. The 2025 EFSA opinion re-examined neotame (E 961) as a food additive, drawing together the toxicological database and dietary exposure estimates available at the time (PMID 40626198). In the human trial described above, neotame was delivered in a baked food and the researchers reported appetite and endocrine outcomes as the primary measures rather than a treatment-emergent adverse event profile (PMID 38553262). Claims circulating outside the peer-reviewed literature about neotame and gut or metabolic harm are not represented in the verified papers cited here, and this page does not extend beyond what those papers state. This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to diet, health conditions or medication.

Why It Matters to Peptide Readers

Neotame appears in peptide discussions for three reasons. First, terminology: people searching peptide topics encounter it as a "dipeptide sweetener" and reasonably ask whether it behaves like the peptides they are reading about. It does not — it has no receptor-mediated signalling role and no therapeutic use. Second, chemistry: it demonstrates how modifying an amino-acid backbone with an alkyl group or an ester changes stability, a concept central to why many peptides are modified before study (PMID 26593524). Third, because it contains a phenylalanine residue, discussion of phenylalanine exposure from amino-acid-based additives sits inside formal safety assessment work rather than inside peptide pharmacology (PMID 40626198).

Limitations of the Current Evidence

1. Human data in the verified set come from one randomised crossover trial in a specific population using a specific food vehicle (PMID 38553262).
2. The longest human exposure period described in that trial was two weeks, so longer-term outcomes were not addressed by it (PMID 38553262).
3. Stability findings were matrix-specific: they described flavoured milk under defined heat treatments, not all foods (PMID 26593524).
4. Regulatory opinions are periodically revisited as data accumulate, and the 2025 re-evaluation reflects the evidence base available to it (PMID 40626198).

References

• Acute and two-week effects of neotame, stevia rebaudioside M and sucrose-sweetened biscuits on postprandial appetite and endocrine response in adults with overweight/obesity — a randomised crossover trial from the SWEET consortium (EBioMedicine, 2024)
• Stability of aspartame and neotame in pasteurized and in-bottle sterilized flavoured milk (Food Chemistry, 2016)
• Re-evaluation of neotame (E 961) as food additive (EFSA Journal, 2025)